YS Biopharma Co., Ltd.

The momentum for this stock is not very good. YS Biopharma Co., Ltd. is not very popular among insiders. Tradey thinks it is not wise to invest in YS Biopharma Co., Ltd..

News

YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nYS stock results show that YS Biopharma Co missed analyst estimates for earnings per share but beat on revenue for the third quarter of...\n more…

YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

Seeking Alpha: Transcripts YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript...\n more…

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

PR Newswire YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 PR...\n more…

YS Biopharma: YS-HBV-002 vaccine granted clinical trial approval by PFDA

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

PR Newswire YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus...\n more…

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

PR Newswire YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility PR Newswire GAITHERSBURG, Md., April 3, 2024 GAITHERSBURG...\n more…